Dirk Thye - Aug 29, 2024 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: CEO AND CHIEF MEDICAL OFFICER, Director
Signature: /s/ Dirk Thye
Stock symbol: QNCX
Transactions as of: Aug 29, 2024
Transactions value $: $107,375
Form type: 4
Date filed: 9/3/2024, 05:38 PM
Previous filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNCX	Common Stock	Purchase	$53.5K	+77.5K	+11.24%	$0.69	767K	Aug 29, 2024	Direct	F1
transaction	QNCX	Common Stock	Purchase	$53.9K	+77K	+10.04%	$0.70	844K	Aug 30, 2024	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.66 to $0.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.67 to $0.72, inclusive.